Saturday, April 25, 2020, San Diego, California, 7:00 PM – 9:00 PM

Data + Perspectives: Clinical Investigators Explore the Biology Underlying the Role of PARP Inhibition in the Management of Common Cancers

Update regarding COVID-19

The AACR Board of Directors has announced it will not conduct the 2020 AACR Annual Meeting, April 24-29 in San Diego, California. A rescheduled meeting is being planned for later this year. For up-to-date information on this program, please sign up for our email alerts.

Last updated 4/8/2020

Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101
Hotel Phone: (619) 232-1234

Time
6:30 PM – 7:00 PM — Registration and Buffet Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Harbor Ballroom GHI (Second Level — Harbor Tower)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty
Johann S de Bono, MBChB, MSc, PhD
Professor of Experimental Cancer Medicine and
Honorary Consultant in Medical Oncology
Head of Clinical Studies Division
Head of Drug Development Unit
Head of Prostate Cancer Targeted Therapy Group
The Institute of Cancer Research and Royal
Marsden NHS Foundation Trust
Sycamore House
Sutton, Surrey, United Kingdom

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Additional faculty to be announced
Moderator
Sulfi Ibrahim, MD
Hematology/Oncology
Reid Memorial Hospital
Richmond, Indiana


This symposium is accredited by Research To Practice and supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck. This is not an official program of the American Association for Cancer Research Annual Meeting.

This CME symposium will feature 4 clinical investigators reviewing available clinical and translational research and ongoing investigation informing the role of poly(ADP-ribose) polymerase (PARP) inhibitors in the management of ovarian, breast, pancreatic and prostate cancer. The program will be moderated by a general medical oncologist with a wealth of expertise in caring for patients with the aforementioned diseases.

The agenda will be divided into 4 distinct modules, each focused on PARP inhibition in 1 of the 4 cancer types and featuring a blend of case presentations, moderated discussion and a faculty member-led review of available data, ongoing clinical trials and translational research findings. To begin each module, one of the panelists will present cases from his or her practice of patients who received a PARP inhibitor. Each case discussion will attempt to frame a handful of educational issues and allow the faculty member to describe how he or she currently thinks through these situations. The moderator will then invite the other faculty members to provide their perspectives on the cases presented and the degree to which the central questions and issues are relevant to the treatment of the other 3 diseases. After this case discussion, the presenting faculty member will deliver a brief review of available and emerging research specific to the current and/or future role of PARP inhibition in their area of expertise. To enhance the program focus, clinician attendees will be provided with networked iPads® to complete a premeeting survey centered on the cases and topics to be presented and discussed. Survey results will be reviewed throughout each module and used to augment the discussion segments.

A detailed agenda will be made available in the coming weeks.

Target Audience
This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and scientific and research professionals involved in basic, translational and clinical cancer research or treatment.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Understand how DNA damage-repair (DDR) pathway abnormalities can be targeted via PARP inhibition to elicit therapeutic benefit.
  • Consider the correlation between BRCA1/2 mutations and the development of hereditary cancers, and counsel patients with these genetic abnormalities regarding their long-term outlook and therapeutic options.
  • Appraise available guideline recommendations and consensus statements on the indications and evidence-based modalities for genetic testing in ovarian, breast, pancreatic and prostate cancer, and use the results of these assessments to guide treatment planning with PARP inhibitors, including as part of clinical trial accrual.
  • Appreciate available clinical trial data with FDA-approved PARP inhibitors for patients with ovarian cancer in different disease settings, and safely integrate these agents into routine clinical care.
  • Evaluate the recent FDA approval of PARP inhibitors for patients with HER2-negative metastatic breast cancer harboring a germline BRCA mutation, and discern how these agents can be appropriately and safely integrated into routine clinical practice.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the commercially available and investigational PARP inhibitors to better understand the activity and toxicities of these agents.
  • Recall the recent FDA approval of PARP inhibition as maintenance therapy for patients with metastatic pancreatic cancer with a BRCA mutation who have not experienced disease progression on first-line platinum-based chemotherapy, and identify individuals for whom this strategy can be employed.
  • Describe the rationale for testing patients with metastatic prostate cancer for mutations in homologous DNA recombination repair genes, and inform individuals found to harbor these genetic abnormalities of the outcomes from clinical trials evaluating PARP inhibition.
  • Describe mechanisms of acquired tumor resistance to PARP inhibitors, and identify investigational combination therapeutic opportunities to circumvent this process.
  • Understand the biologic rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches with PARP inhibitors for patients with DDR deficiencies, and recommend appropriate trials to eligible patients.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101
Hotel Phone: (619) 232-1234

Meeting Room
Harbor Ballroom GHI (Second Level — Harbor Tower)